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Two missense mutations in KCNQ1 cause pituitary
hormone deﬁciency and maternally inherited
gingival ﬁbromatosis
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Familial growth hormone deﬁciency provides an opportunity to identify new genetic causes of
short stature. Here we combine linkage analysis with whole-genome resequencing in patients
with growth hormone deﬁciency and maternally inherited gingival ﬁbromatosis. We report
that patients from three unrelated families harbor either of two missense mutations,
c.347G>T p.(Arg116Leu) or c.1106C>T p.(Pro369Leu), in KCNQ1, a gene previously
implicated in the long QT interval syndrome. Kcnq1 is expressed in hypothalamic GHRH
neurons and pituitary somatotropes. Co-expressing KCNQ1 with the KCNE2 β-subunit shows
that both KCNQ1 mutants increase current levels in patch clamp analyses and are associated
with reduced pituitary hormone secretion from AtT-20 cells. In conclusion, our results reveal
a role for the KCNQ1 potassium channel in the regulation of human growth, and show that
growth hormone deﬁciency associated with maternally inherited gingival ﬁbromatosis is an
allelic disorder with cardiac arrhythmia syndromes caused by KCNQ1 mutations.
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Somatic growth mirrors nutritional status, general health,and psychosocial well-being, and is also affected by inher-ited and epigenetic factors. An essential role in human
growth is played by growth hormone which is secreted by the
anterior pituitary somatotropes, mainly under the inﬂuence of
hypothalamic inputs such as growth hormone-releasing hormone
(GHRH) and somatostatin1. Childhood onset of growth hormone
deﬁciency (GHD) is a clinically heterogeneous condition and
deﬁning its cause is important for diagnostics and treatment.
Studying familial GHD provides an opportunity to identify
genetic regulators of growth hormone secretion and pituitary
function. The most common genes implicated in the genetic
etiology of GHD are GH1 (MIM: 139250, Online Mendelian
Inheritance in Man, http://www.omim.org/), encoding growth
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Fig. 1 Pedigrees, gingival ﬁbromatosis and craniofacial features, and KCNQ1 structure. a (I) Pedigree of the large Finnish family showing autosomal
dominant growth hormone deﬁciency and maternally inherited gingival ﬁbromatosis. The genotype (wild-type (WT) or p.(Arg116Leu)) is given. The
samples included in the linkage analysis are indicated in italics, and samples included in whole-genome sequencing are underlined. Two additional families
with the same disease but another mutation in KCNQ1, p.(Pro369Leu), were identiﬁed: a Finnish trio (II) and a family (III) originating from Argentina. Note
that the index patient in pedigree III has a de novo mutation. bMaternally inherited gingival ﬁbromatosis is shown together with the craniofacial features of
the twin boys belonging to family II. c Schematic of the KCNQ1 channel protein and the location of the two missense mutations in the 3D channel structure.
The schematic shows the membrane domain, with helical segments S0–S6 and the intracellular domain, divided into a membrane-proximal module (helices
A–B) bound by CaM and a distal module (helices C–D), responsible for tetramerization. Filled circles with labels show the positions of the mutations,
Arg116Leu and Pro369Leu. The double lines depict the plasma membrane. Below the schematic is a molecular graphics depiction of the Kv7.1/CaM channel
complex as based on the cryo EM Xenopus structure (PDB code: 5VMS)11. The channel subunits are colored green, cyan, and teal. CaM is colored pink and
shown with a surface representation on the right side. Gray spheres are Ca2+ ions. Again, the straight lines denote the probable location of the plasma
membrane. The residues that undergo mutation are drawn as CPK atoms and are labeled. One channel subunit of the tetramer and its respective CaM
molecule have not been drawn in order to facilitate visualization. The helix D tetrameric coiled-coil62 was not observed in the cryo EM study due to
ﬂexibility in the linker between it and helix C and hence not drawn here
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01429-z
2 NATURE COMMUNICATIONS |8:  1289 |DOI: 10.1038/s41467-017-01429-z |www.nature.com/naturecommunications
hormone (GH), and GHRHR (MIM: 139191), encoding the
receptor for GHRH2. GHD may also result from mutations in
genes that encode transcription factors involved in pituitary
development: HESX1 (MIM: 601802), OTX2 (MIM: 600037),
SOX2 (MIM: 184429), SOX3 (MIM: 313430), LHX3
(MIM: 600577), PITX2 (MIM: 601542), PROP1 (MIM: 601538),
POU1F1 (MIM: 173110), and TCF7L1 (MIM:604652)1,3. Some
of these mutations are associated with additional pituitary
hormone deﬁciencies and developmental abnormalities, such as
variants of septo-optic dysplasia (MIM: 182230), ocular defects,
ectopic posterior pituitary, skeletal defects, and intellectual
impairment1.
Occurrence of growth retardation due to GHD in combination
with gingival ﬁbromatosis (GF), described hitherto in three
families4–6, suggests a previously unidentiﬁed genetic cause of
GHD. Here we report that this syndrome is caused by two mis-
sense mutations, c.347G>T p.(Arg116Leu) or c.1106C>T p.
(Pro369Leu), in KCNQ1, a gene that encodes the alpha subunit of
the voltage-gated ion channel Kv7.1, previously implicated in
cardiac arrhythmia syndromes7–9. We demonstrate the expres-
sion of Kcnq1 in hypothalamic GHRH neurons and pituitary
somatotropic cells. Both mutants increase current levels in patch
clamp analyses, especially when co-expressed with the auxiliary
KCNE2 β-subunit. Mutant KCNQ1s also lead to reduced pitui-
tary hormone secretion from AtT-20 cells when coexpressed with
KCNE2. Taken together, our results demonstrate that two mis-
sense mutations in KCNQ1 cause pituitary hormone deﬁciency
and maternally inherited GF in humans.
Results
Pedigree and genetic analysis. We performed genome-wide
linkage analysis in a large Finnish family4 (Fig. 1a) with this
disease, and found statistically signiﬁcant linkage, logarithm of
odds (LOD) score> 3.3, between the studied phenotype and a
locus on 11p15. The highest LOD score, 3.54, was reached with
the marker rs7947959 (hg19 chr11:4784679). The most distal
marker showing statistically signiﬁcant linkage was located at
286 kb and the most proximal marker at 11.36 Mb. No other
chromosomal areas reached LOD scores >3.0. We then per-
formed whole-genome resequencing (Beijing Genomics Institute)
in two affected family members. Novel variants in the linkage
region shared between the two genomes, and not found in any
databases (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/; Exome
Variant Server, http://evs.gs.washington.edu/EVS/; 1000 Gen-
omes, http://www.1000genomes.org/; ExAC, http://exac.
broadinstitute.org/), were annotated with SNPnexus (http://
www.snp-nexus.org/). The c.347G>T p.(Arg116Leu) missense
mutation in KCNQ1 (MIM: 607542), shared between the two
genomes, was left in the linkage region after known variants,
variants in the noncoding regions, and the synonymous changes
were ﬁltered out. PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/) predicted this mutation to be deleterious with very high
probability (score 0.993). The presence or absence of the muta-
tion was veriﬁed by Sanger-sequencing in all 16 family members,
and in four additional affected family members participating in
the study after completion of linkage analysis. The mutation
segregated with GHD and/or short stature in the family and was
Table 1 Summary of phenotypic features in patients with KCNQ1 mutations p.(Arg116Leu) or p.(Pro369Leu) and pituitary
hormone deﬁciencies
Subject KCNQ1
mutation
Sex QTc
interval in
ECG (ms)
Height (SDS) at the age
of the onset of GH
therapy
Brain MRI Pituitary hormone
deﬁciencies
Mutation
inherited/ gingival
ﬁbromatosis
Craniofacial
phenotype as a
child
#5 p.R116L F 414 −4.5 at 15 years Normal Growth hormone and
gonadotropin
Maternally/Yes NA
#6 p.R116L F 412 −3.4 at 12.4 years Normal Growth hormone and
gonadotropin
Maternally/Yes NA
#7 p.R116L M 391 −5.0 at 8.5 years Small
hypophysis
Growth hormone,
gonadotropin, ACTH,
and thyrotropin
Maternally/Yes Yes
#13 p.R116L F NA −2.7 at 4.5 years Normal Growth hormone Paternally/No No
#13b p.R116L F NA −2.7 at 3.7 years Normal Growth hormone and
thyrotropin
Paternally/No No
#8 p.R116L M 398 −2.6 at 15.9 years NA Growth hormone and
gonadotropin
Maternally/Yes Yes
#9 p.R116L F NA −2.7 at 9 years NA Growth hormone,
gonadotropin
Maternally/Yes Yes
#15 p.R116L M 363a −1.8 at 6 years Small
hypophysis
with thin stalk
Growth hormone,
gonadotropin
Maternally/Yes Yes
#17 p.R116L M 329a −2.2 at 5 years Small
hypophysis
with thin stalk
Growth hormone,
gonadotropin
Maternally/Yes Yes
#18 p.R116L F 463 −2.3 at 13.4 years Normal Growth hormone Maternally/Yes Yes
#20 p.P369L F 317a −5.2 at 17 years Normal Growth hormone,
gonadotropin, ACTH
and thyrotropin
NA/No No
#21 p.P369L M 399 −3.0 at 2.7 years Small
hypophysis
Growth hormone Maternally/Yes Yes
#22 p.P369L M 358a No GH therapy NA Growth hormone
(no treatment)
Maternally/Yes Yes
#25b p.P369L F 349a NA Normal No treatment De novo/Yes NA
F female, MRI magnetic resonance imaging, M male, NA not available
aQTc time less than the 2nd percentile for gender and age10,11
bShe has a de novo mutation. She has refused endocrine testing. Her two daughters have GF and craniofacial phenotype, and one of them also has microhypophysis and GH deﬁciency diagnosed at 5
years of age
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absent from the SISu database (The Sequencing Initiative Suomi
project, containing over 10,000 Finnish samples, http://www.
sisuproject.ﬁ/). Sanger sequencing of the coding exons and
exon–intron boundaries of the KCNQ1 gene in a second Finnish
family (mother and twin boys) with GHD and GF revealed
another novel missense mutation, c.1106C>T p.(Pro369Leu), in
all three members (Fig. 1a, b). This mutation was also absent
from the dbSNP, Exome Variant Server, 1000 Genomes, ExAC,
and SISu databases and predicted to be probably damaging by
PolyPhen-2 (score 0.960). In the third family, a Swiss family
originating from Argentina (Fig. 1a), the index patient carried the
same c.1106C>T p.(Pro369Leu) mutation as de novo.
Phenotypic features of KCNQ1 mutation carriers. Detailed
clinical histories of mutation carriers are provided in Supple-
mentary Note 1, and the summary of phenotypic features are
given in Table 1. Patients carrying either the p.(Arg116Leu) or the
p.(Pro369Leu) mutation in KCNQ1 displayed a wide endocrine
phenotypic spectrum that ranged from relatively mild (only low
IGF-1 levels in patients #10 and #11, or GF in subject #14)
through classic GHD to multiple pituitary hormone deﬁciencies
(Supplementary Note 1, Table 1). Several mutation carriers had
GF (Fig. 1b) and mild craniofacial dysmorphic features, but only
when the mutation was inherited from the mother (Table 1). One
patient had retinal pigmentation (Supplementary Fig. 1). We
therefore veriﬁed the expression of KCNQ1 in the developing
human retina (Fig. 1b).
KCNQ1 mutations are associated with alterations in the QT
interval duration. Five of the 12 mutation carriers examined
(42%, 95% conﬁdence interval 20–68%) displayed a corrected QT
interval below the 2nd percentile of age- and gender-matched
reference values, and two of them fulﬁlled the diagnostic criteria
for short QT syndrome (Table 1)10–12.
Molecular modeling of KCNQ1. We mapped the location of
the two mutations to the 3D channel structure (Fig. 1c). KCNQ1
has six transmembrane segments (S1–S6) and intracellular
N- and C-termini (CT). Arg116 is located in the N-terminus and
Pro369 at the C-terminus. Both residues are proximal to the
membrane13. Arg116 interacts with and Pro369 maps to an
intracellular gating module, comprised of the proximal CT and
constitutively bound CaM. The gating module directly connects
to and regulates the activation gate in the sixth transmembrane
segment (S6) that is responsible for opening and closing the
channel pore14 (Fig. 1c).
Functional channel expression requires calmodulin (CaM),
the ubiquitous calcium binding protein15,16 that serves as an
obligate subunit of the channel complex, bound intracellularly.
The biochemical properties of the Pro369Leu mutant was
tested by using a pull-down assay of the intracellular CT to test
binding of CaM. However, the Pro369Leu mutation does not
compromise the structural integrity of the proximal C-terminal
(CT)/CaM complex (Supplementary Figs. 2 and 3).
Patch-clamp analyses and heart phenotypes of patients. The
electrophysiological properties of the mutated channels were
examined in whole-cell patch-clamp analyses in HEK 293 cells, in
which both mutated channels (p.Arg116Leu and p.Pro369Leu)
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Fig. 2 Electrophysiological studies of the WT, KCNQ1-Arg116Leu and KCNQ1-Pro369Leu mutant KCNQ1 proteins. a Representative recordings of currents
measured during the voltage-clamp protocol (shown in inset with scale bars) in HEK293 cells transfected with cDNAs encoding wild-type (WT) or mutant
(p.Arg116Leu, p.Pro369Leu) KCNQ1 potassium channels: KCNQ1 alone (top row), KCNQ1 and KCNE1 (middle row), or KCNQ1 and KCNE2 (bottom row).
b Respective current-voltage relationships normalized for cell size. Peak current analysis was performed at the end of each voltage step. pA/pF:
picoamperes per picofarad. c Normalized activation curves, measured 2–4ms after stepping to −30mV, as a function of the prior voltage potential. KCNQ1
and KCNQ1/KCNE1 conductance-voltage relation values were ﬁtted to a Boltzmann function. The time constants and slope values were; KCNQ1 WT:
−26.2± 2.9mV, 8.6± 0.9 (n= 14/3), KCNQ1-R116L: −16.1± 1.5 mV, 6.9± 0.3 (n= 21/4), KCNQ1-P369L: −30.9± 2.5 mV, 6.9± 0.6 (n= 14/3), KCNQ1
WT+KCNE1: 21.0± 2.5 mV, 16.2± 1.7 (n= 18/3), KCNQ1-R116L+KCNE1: 42.4± 3.6 mV, 12.7± 1.7 (n= 11/2), KCNQ1-P369L+KCNE1: 7.3± 3.8 mV,
14.7± 0.6 (n= 18/3). Mean± SEM values are shown. *P< .05, **P< .01, ***P< .001 vs. WT. G/Gmax: conductance of the channel relative to its
maximal conductance
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gave higher current levels than the wild-type (WT) Kv7.1 chan-
nels when expressed alone (P< 0.05–0.001), and notably,
the activation kinetics of KCNQ1-Arg116Leu was shifted to
more depolarized values (Fig. 2). Potassium channels comprised
of KCNQ1 and KCNE1 subunits are responsible for one of
the primary cardiac repolarizing currents, the slow delayed
rectiﬁer current (IKs)17, and mutations in KCNQ1 are known to
cause the long QT syndrome7,8 (LQT1, MIM: 192500) and the
rare short QT syndrome8,9 (MIM: 609621). The electro-
physiological properties of the mutated channels were therefore
also examined when KCNQ1 was co-expressed with KCNE1.
Ectopically expressed KCNQ1-Pro369Leu/KCNE1 Kv7.1 chan-
nels gave profoundly increased currents (Fig. 2), whereas the
currents produced by KCNQ1-Arg116Leu/KCNE1 Kv7.1 chan-
nels at +60 mV did not differ from the control, but still, the
voltage dependence of activation kinetics were shifted to more
depolarized potentials (Fig. 2). Co-expressing KCNQ1 with
KCNE2, another β subunit expressed in a number of other tissues
together with KCNQ118,19, showed that both KCNQ1-Pro369-
Leu/KCNE2 and KCNQ1-Arg116Leu/KCNE2 increased the
current levels (P< 0.05–0.001) (Fig. 2). Taken together, these
results suggests that the Pro369Leu and Arg116Leu mutations
impart subtle but distinct conformational changes to this module
that favor the open channel state, in particular when assembled
with KCNE2.
Expression of KCNQ1 in mouse and human. We studied the
expression of KCNQ1 in growth-regulating hypothalamic and
pituitary cell types in mice by using immunoﬂuorescence and
mRNA in situ hybridization techniques. KCNQ1 expression was
also examined by RT-PCR in human hypothalamic and pituitary
gland cDNA. Our results show that KCNQ1 is expressed in
mouse somatotrope and gonadotrope cells in the postnatal
pituitary (Fig. 3a, b), and in the human pituitary (Supplementary
Fig. 4a). Kcnq1 was also expressed in mouse hypothalamic GHRH
neurons during development, and in the human hypothalamus
(Fig. 3b and Supplementary Fig. 4b). Finally, Kcnq1 was
expressed along the blood vessels of the developing mouse
pituitary, and KCNQ1was detected along the postnatal pituitary
capillaries by immunostaining (Fig. 3a, c). We also veriﬁed the
expression of KCNE2 in human hypothalamus and pituitary
(Supplementary Fig. 4c).
ACTH secretion assay and protein expression quantiﬁcation.
The impact of KCNQ1 on pituitary hormone secretion was
investigated by transiently overexpressing WT or one of the
mutant KCNQ1s (p.Arg116Leu, p.Pro369Leu) in the well-char-
acterized, ACTH-secreting mouse pituitary tumor cell line
AtT-20/D16v-F2, widely used to investigate the regulation of
exocytosis by voltage-gated calcium entry20,21. The LQT1-causing
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Fig. 3 KCNQ1 is expressed in cells of the mouse hypothalamic–pituitary growth hormone axis. a Immunoﬂuorescence staining against KCNQ1 (red) and
Growth Hormone (GH, green) reveals membranous expression of KCNQ1 in a subset of GH-expressing cells of the postnatal pituitary at day 17 (P17, yellow
arrowhead) as well as expression in additional pituitary cell types (white arrowhead) and surrounding blood vessels (arrows). b Sensitive RNAscope in situ
hybridization detects Kcnq1 mRNA (aqua) in Ghrh-expressing neurons of the developing hypothalamus (red) at 17.5 days post coitum (dpc), and conﬁrms
the expression in Gh-expressing somatotropes (red) at P17. Kcnq1 is expressed in additional endocrine cells types such as Lhb-expressing gonadotropes
(red). Examples of double-positive cells are noted by yellow arrowheads. c Kcnq1 mRNA is detected in cells surrounding blood vessels of the developing
anterior pituitary at 15.5 dpc. Scalebars indicate 100 μm in low magniﬁcation images and 20 μm in high magniﬁcation images. AL anterior lobe, BV blood
vessel, Ht hypothalamus, IL intermediate lobe, 3v third ventricle
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p.Gly589Asp mutant, which is a founder mutation in the Finnish
population, served as an additional control. ACTH levels pro-
duced by cells transfected with the mutant KCNQ1s did not differ
from the reference condition (WT KCNQ1) (Table 2). In con-
trast, ACTH levels produced by cells transfected with KCNQ1-
Arg116Leu or KCNQ1-Pro369Leu together with KCNE2 were
signiﬁcantly lower than those produced by the cells
transfected with the WT KCNQ1 and KCNE2 (P< 0.001 and
P= 0.004, respectively) (Table 3). We subsequently examined
whether the observed differences in ACTH levels could be
explained by relative expression levels of the mutant constructs.
Relative expression of the p.Pro369Leu did not differ from
the WT KCNQ1, whereas the expression of p.Arg116Leu was
lower than that of the WT KCNQ1 (P< 0.05) (Supplementary
Figs. 5 and 6). The lowest relative expression was exhibited by the
additional control (p.Gly589Asp) (P< 0.005 vs. WT KCNQ1).
Importantly, however, the ACTH levels produced by the cells
transfected with the KCNQ1-Gly589Asp and KCNE2 did
not differ from the WT condition (Table 3), suggesting that
the differences in relative KCNQ1 expression levels did not
determine the ACTH levels measured in the culture medium.
Protein–protein interaction studies. We next examined the
possibility that the two KCNQ1 mutations may disrupt critical
protein–protein interactions. We explored this by expressing
KCNQ1 in Flp-In T-REx 293 cells, and found 68 high-conﬁdence
interacting partners that were involved in processes such as
spliceosomal snRNP assembly and intracellular trafﬁcking (Sup-
plementary Fig. 7a). However, the protein–protein interaction
heatmap did not reveal gross differences among the strongest
interactors between the WT KCNQ1 and KCNQ1-Arg116Leu or
KCNQ1-Pro369Leu (Supplementary Fig. 7b).
Discussion
We identiﬁed two missense mutations in KCNQ1 to underlie
childhood onset of GHD and maternally inherited gingival
ﬁbromatosis. Very recently, maternally inherited variation in the
KCNQ1 locus was shown to associate with reduction in adult
height in the Sardinian population22. Inheritance of GHD in our
families, however, followed an autosomal dominant pattern, and
similarly, a lack of a parent-of-origin effect has been described in
the long QT syndrome caused by loss-of-function KCNQ1
mutations23. The KCNQ1 locus resides in the imprinted region of
chromosome 11p15, and during early ontogenesis, KCNQ1 is
paternally imprinted. In our patients, only those with a mater-
nally inherited KCNQ1 mutation displayed congenital GF, and
several of them also had mild craniofacial dysmorphic features
that were mitigated by adulthood, suggesting loosening of
KCNQ1 imprinting in cranial tissues with age, similarly as
reported to occur in the pancreas24. The two twin pairs (mono-
zygotic twins #7 and #8 and dizygotic twins #21 and #22), present
in our families, are prismatic for understanding the phenotypic
variability: subject #21 was smaller than his brother at birth, and
had a more severe endocrine phenotype (Supplementary Note 1,
Table 1). Similarly, subject #7, who was born breech and smaller
than his monozygotic twin brother, had more severe growth
failure during childhood (Supplementary Note 1, Table 1). Thus,
environmental factors are likely to modify the endocrine phe-
notype of this syndrome. We also found a spectrum of corrected
QT intervals in the mutation carriers, which indicates incomplete
penetrance and variable expressivity of the mutations in the heart,
similarly as described for long QT syndrome due to loss-of-
function KCNQ1 mutations25.
Our results show that KCNQ1 is expressed in mouse soma-
totrope and gonadotrope cells in the postnatal pituitary and in the
human pituitary. Indeed, previous ﬁndings have implicated
voltage-gated potassium channel currents in pituitary cells in
different species26–28. Kcnq1 was also expressed in mouse hypo-
thalamic GHRH neurons during development, and in the human
hypothalamus. These ﬁndings raise the possibility that the
Arg116Leu and Pro369Leu KCNQ1 mutations may impact
hypothalamic–pituitary function at multiple levels; in the case of
the growth hormone axis, both on the control of episodic GHRH
secretion by hypothalamic neurons as well as on somatotrope
function during growth. Kcnq1 was also expressed along the
blood vessels of the developing mouse pituitary, and KCNQ1 was
detected along the postnatal pituitary capillaries by immunos-
taining. Somatotropes are organized in the close vicinity of
pituitary blood vessels29, and GHRH enhances the oxygen supply
to the somatotrope network via increased capillary blood
ﬂow29,30. The anterior pituitary is richly vascularized by fene-
strated capillaries emanating from the pituitary portal system, and
direct arterial supply has also been demonstrated in human
pituitary adenomas31–33. Although voltage-gated potassium
channels, including KCNQ1, are implicated in the vascular
physiology34, their possible role, if any, in the regulation of
pituitary blood ﬂow is currently unknown.
Although the exact mechanism by which the two KCNQ1
mutations cause pituitary hormone deﬁciency in humans is
unclear, our data suggest that the KCNQ1–KCNE2 complex may
play a role in it. Co-expressing KCNQ1 with KCNE2 β-subunit
showed that both KCNQ1 mutants increased current levels in
patch clamp analyses and were associated with reduced pituitary
hormone secretion from AtT-20 cells. Both KCNQ1 and KCNE2
have been implicated in exocytosis35,36, and our electro-
physiological and hormone secretion data suggest that the p.
Arg116Leu and p.Pro369Leu mutations increase potassium con-
ductance, which via hyperpolarization leads to diminished hor-
mone secretion. The presence of KCNE2 expression in human
hypothalamus and pituitary tissues is in agreement with the
previously observed expression of Kcne2 in rodents37,38, and thus
lends credence to the above hypothesis. Intriguingly, KCNE2 can
regulate several different Kv channels, and plays an important
role in the endocrine system. Kcne2 deletion causes hypothyr-
oidism in pregnant and lactating mice and in their pups18, and
very recently Kcne2−/− mice were reported to have impaired
glucose-induced insulin secretion36. In light of the mutations’
location in the 3D channel structure, the electrophysiological
ﬁndings, and our observation that neither mutation compromises
the integrity of the proximal CT/CaM gating module, i.e., CaM
association with the CT, we conclude that the Pro369Leu and
Arg116Leu mutations probably favor the open channel state
especially when assembled with the KCNE2 β subunit.
Table 2 Mixed linear regression model estimates for ACTH
concentrations (ng/ml) measured in diluted medium
samples from cells transfected with KCNQ1
Parameter Estimate SE p
Intercept (WT KCNQ1)a 7.26 0.99 <0.001
Time 0.76 0.25 0.004
KCNQ1-Arg116Leu 0.32 0.72 0.659
KCNQ1-Pro369Leu 0.62 0.72 0.393
KCNQ1-Gly589Asp 1.11 0.72 0.126
Mixed linear regression model estimates for ACTH concentrations (ng/ml) measured in diluted
medium samples (1:10) in the reference condition (WT KCNQ1) and three other KCNQ1
conditions (KCNQ1-Arg116Leu, KCNQ1-Pro369Leu, KCNQ1-Gly589Asp), their standard errors
(SE), and corresponding P values. The model included both the growth time (per 1 h) and the
KCNQ1 conditions as ﬁxed effects and the experiment number as a random intercept. ACTH
levels produced by the cells transfected with mutant KCNQ1s did not differ from the levels
produced by the WT KCNQ1. Similarly, the CRF-induced ACTH secretion did not differ between
the four KCNQ1 environments (data not shown)
aAt −2 h
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The protein–protein interaction heatmap did not reveal gross
differences among the strongest interactors between the WT
KCNQ1 and KCNQ1-Arg116Leu or KCNQ1-Pro369Leu. Thus,
rather than resulting from a speciﬁc protein–protein interaction
defect(s), this syndrome may primarily arise from altered potas-
sium channel balance in different cell types, with variable mani-
festations depending on the interplay with environmental factors.
Indeed, patients that carry mutations in other potassium channels
share phenotypic similarities with our patients: a craniofacial
phenotype, GHD and hypogonadotropic hypogonadism have
been reported in a patient with Cantù syndrome (MIM: 239850)
39, caused by gain-of-function mutations in ABCC9 or KCNJ840,
gingival ﬁbromatosis/overgrowth in patients carrying mutations
in KCNJ641 and KCNH142, and a craniofacial phenotype in
patients with mutations in KCNJ641, KCNJ243, and KCNK944.
One possible explanation for the cranial phenotype and GF stems
from altered potassium channel balance in the cranial neural
crest45, a transient cell population which gives rise to the bone
and cartilage in the cranial area, and to 90% of gingival
mesenchymal stem cells46. Of note, cyclosporine A has been
proposed to activate KCNQ147, and this immunosuppressive
agent also frequently causes GF as a side effect. Thus, it is possible
that KCNQ1 activation plays also a role in drug-induced GF.
In conclusion, our results reveal a role for the potassium
channel protein KCNQ1 in the regulation of human growth, and
show that GHD associated with maternally inherited gingival
ﬁbromatosis, long QT syndrome7,8, short QT syndrome8,9,
familial atrial ﬁbrillation48 (MIM: 607554), and Jervell and Lange-
Nielsen cardioauditory syndrome49 (MIM: 220400) are allelic
disorders. Ion channels are known to regulate several processes in
the pituitary cells26,50. Our work builds on these previous
observations and demonstrates that ion channels are clinically
relevant regulators of pituitary function in humans.
Methods
Ethics. This study was approved by the ethics committees of the Oulu University
Hospital, Finland, and the Helsinki University Central Hospital, Finland. The DNA
from family members recruited in Switzerland was obtained by permission of the
Swiss Society of Medical Genetics. All participants gave written informed consent.
Subjects. Members of three unrelated families were recruited: a large Finnish
family, a second Finnish family, and a Swiss family originating from Argentina.
Their phenotypes were ascertained by physical examination, medical records, or,
occasionally, self-report. Phenotypic information on patients 5–9 (Fig. 1) was
described earlier4. DNA was extracted from peripheral blood leukocytes of the
subjects (once from saliva, DNA Genotek, Inc.). A 12-lead ECG was obtained from
12 mutation carriers for evaluation of conduction times. Corrected QT interval
(QTc) was calculated from the QT and inter-beat (RR) interval using Bazett’s
correction (QTc=QT/(RR)½). Hormone measurements were done in the clinical
laboratory.
Linkage analysis. We performed genome-wide single-nucleotide polymorphism
(SNP) genotyping of 16 family members (Illumina HumanOmniExpress micro-
array, Institute for Molecular Medicine Finland) of the large Finnish pedigree.
Two-point parametric linkage analysis was performed using Pseudomarker
1.0.6 software with FASTLINK 4.1P linkage package51,52. Individuals with GF and/
or GHD with short stature or low insulin-like growth factor 1 (IGF-1) levels were
treated as affected; all others were considered healthy. A dominant model of
inheritance with nearly complete penetrance was assumed: disease allele frequency
was set to 0.0001 with a penetrance rate of 0.999 and a phenocopy rate of 0.001.
Allele frequencies were calculated from the genotypes of all individuals.
Identiﬁcation of shared variants. Shared variants within the linkage region in two
affected members of the large Finnish family (Fig. 1a) were examined by whole
genome sequencing (Beijing Genomics Institute). Novel variants in the linkage
region shared between the two genomes and not found in any databases (dbSNP,
http://www.ncbi.nlm.nih.gov/SNP/; Exome Variant Server, http://evs.gs.
washington.edu/EVS/; 1000 Genomes, http://www.1000genomes.org/) were anno-
tated with SNPnexus (http://www.snp-nexus.org/).
Segregation analyses and sanger sequencing of KCNQ1. The Arg116Leu mis-
sense mutation in KCNQ1 was Sanger-sequenced in all 16 family members and in
four additional affected family members participating in the study after completion
of linkage analysis. The mutation was also screened in 200 healthy controls
(anonymous blood donors from the Finnish Red Cross Blood Service). Additional
rare variants shared between the two genomes, upstream and downstream of
KCNQ1, were genotyped in the family to construct haplotypes. Coding exons and
exon–intron boundaries of KCNQ1 were then sequenced in the second Finnish
family (mother and twin boys), as well as in the index patient from the family
originating from Argentina and her parents (Fig. 1a). The primers used in the
Sanger sequencing of KCNQ1 are listed in Supplementary Table 1. PCR conditions
are available upon request.
Electrophysiological studies. The electrophysiological properties of the
Arg116Leu and Pro369Leu KCNQ1 mutants were studied by whole-cell patch
clamping, as described53. In brief, the two mutations were introduced into the
pXOOM-hKCNQ1 expression plasmid. HEK293 cells were transiently cotrans-
fected with 1 µg pXOOM-hKCNQ1 (WT or mutants), 1 µg pcDNA3-hKCNE1/
hKCNE2 for the KCNQ1/KCNE experiments, and 0.2 µg of pcDNA3-eGFP as a
reporter gene, using Lipofectamine 2000 (Invitrogen), according to the manu-
facturer’s instructions. Patch-clamp experiments were performed at room tem-
perature (20–22 °C) 2–3 days after transfection. Patch-clamp recordings were
conducted using an internal solution containing the following (mM): KCl (140),
Na2-ATP (1), EGTA (2), HEPES (10), CaCl2 (0.1), MgCl2 (1), and D-glucose (10),
pH 7.4 with KOH; external solution NaCl (140), KCl (4), CaCl2 (2), MgCl2 (1),
HEPES (10), and D-glucose (10), pH 7.3 with NaOH. Cells expressing WT or
mutant KCNQ1 potassium channels, detected by green ﬂuorescence, were sub-
jected to voltage clamping to detect potential changes in activation and inactivation
kinetics.
Statistics for electrophysiological studies. For electrophysiological studies,
mean± SEM values are shown. Statistical signiﬁcance was evaluated by two-way
analysis of variance (ANOVA) with Bonferroni correction. P< 0.05 was considered
statistically signiﬁcant.
ACTH secretion studies and western blotting. AtT20-20/D16v-F2 cells (Sigma)
were maintained in DMEM (Sigma) supplemented with 10% FBS (v/v) (HyClone),
penicillin (25 U/ml, Sigma), streptomycin (25 U/ml, Sigma), and 2 mM glutamine
(Invitrogen). At the beginning of each experiment, the cells were seeded on 24-well
Table 3 Mixed linear regression model estimates for ACTH concentrations (ng/ml) measured in diluted medium samples from
cells transfected with KCNQ1 and KCNE2
Parameter Estimate SE P
Intercept (WT KCNQ1/KCNE2)a 9.59 0.84 <0.001
Time 0.62 0.15 <0.001
KCNQ1-Arg116Leu/KCNE2 −1.88 0.42 <0.001
KCNQ1-Pro369Leu/KCNE2 −1.29 0.42 0.004
KCNQ1-Gly589Asp/KCNE2 −0.77 0.42 0.075
Mixed linear regression model estimates for ACTH concentrations (ng/ml) measured in diluted medium samples (1:10) in the reference condition (WT KCNQ1/KCNE2) and three other KCNQ1
conditions (KCNQ1-Arg116Leu/KCNE2, KCNQ1-Pro369Leu/KCNE2, KCNQ1-Gly589Asp/KCNE2), their standard errors (SE), and corresponding P values. The model included both the growth time (per
1 h) and the KCNQ1/KCNE2 conditions as ﬁxed effects and the experiment number as a random intercept. Based on the regression model, the KCNQ1-Arg116Leu with KCNE2 produced 20% (−2 h) or
17% (0 h) less ACTH than the reference (WT KCNQ1 with KCNE2) (P< 0.001). Similarly, the KCNQ1-Pro369Leu with KCNE2 produced approximately ~12–13% less ACTH (P= 0.004) than the
reference environment. ACTH levels produced by the cells transfected with the LQT1 mutant KCNQ1-Gly589Asp/KCNE2, which served as a control, did not differ signiﬁcantly from the reference
environment. The CRF-induced ACTH responses between the four KCNQ1/KCNE2 conditions did not differ (data not shown)
aAt −2 h
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plates at a density of 90,000 cells per well. The plates were incubated overnight at
37 °C in a humidiﬁed atmosphere of 5% CO2–95% air, and transfected using
Lipofectamine 3000 transfection reagent (Invitrogen) according to manufacturer’s
instructions. Each well received either 500 ng of pXOOM-hKCNQ1 (WT or
mutants Arg116Leu, Pro369Leu, Gly589Asp) alone, or 250 ng of pXOOM-
hKCNQ1 (WT or mutants) together with 250 ng of pcDNA3-hKCNE2 (two wells
for each condition). Thirty hours after transfection, culture medium was changed
to DMEM containing 0.2% (vol/vol) FBS to starve the cells. The ﬁrst medium
samples for ACTH measurements were collected ∼16 h later (−2 h sample) and the
second samples 2 h thereafter (0 h sample). After that, 100 nM CRH (Bachem) was
added to each well, and the third sample was collected 2 h later (+2 h sample). Each
sample was collected by combining media from duplicate wells and samples were
stored at –80 °C until ACTH concentrations were analyzed in diluted aliquots
(1:10) with a commercially available ELISA kit (Phoenix pharmaceuticals, Inc.)
with a sensitivity of 0.08 ng/ml, according to the instructions of the manufacturer.
This experiment was repeated seven times. The data were analyzed as explained the
section Statistical analysis of ACTH secretion studies.
For Western blotting, cells transfected with 250 ng of pXOOM-hKCNQ1
(WT or mutants) together with 250 ng of pcDNA3-hKCNE2 were collected and
combined from duplicate wells 48 h after transfection and lysed in 2× Laemmli
buffer and an equal volume of 8M urea was added. Lysates were sonicated,
incubated at 37 °C for 30 min, and loaded on a 4–20% gradient gel (Bio-Rad).
The proteins were transferred onto a nitrocellulose membrane and detected with
1:1000 rabbit polyclonal α-KCNQ1 antibody (H-130, sc-20816, Santa-Cruz
Biotechnology) and 1:3000 goat α-rabbit IgG (H+L)-HRP conjugate secondary
antibody (#1706515, Bio-Rad) (Supplementary Fig. 5). To control for total
protein loaded on the gel, the blot was stripped with Restore Western Blot
Stripping Buffer (Thermo Scientiﬁc) and β-actin was detected with 1:2000
mouse monoclonal α–β-actin antibody (C4, sc-47778, Santa-Cruz Biotechnology)
and 1:3000 goat α-mouse IgG (H+L)-HRP conjugate secondary antibody
(#1706516, Bio-Rad). KCNQ1 expression was quantitated from three independent
replicates by using Image Studio Lite software (LI-COR Biotechnology). Brieﬂy,
the relative density of all mutants in relation to WT KCNQ1 was calculated,
and the values were adjusted by using the relative density of β-actin of the
corresponding lane.
Statistical analysis of ACTH secretion studies. Two different linear mixed
models were used to explain the ACTH levels measured in diluted (1:10) cell
culture media samples that were obtained after 16 h (−2 h) and 18 h (0 h) of serum
starvation. In the ﬁrst model, the cells had been transfected with four different
KCNQ1s alone (WT KCNQ1, KCNQ1-Arg116Leu, KCNQ1-Pro369Leu, or
KCNQ1-Gly589Asp), and, in the second model, the cells had been transfected with
one of the four KCNQ1 constructs along with the construct encoding the beta
subunit KCNE2.
In both models, the experiment number was included as a random intercept,
and the KCNQ1 environment (WT KCNQ1, KCNQ1-Arg116Leu, KCNQ1-
Pro369Leu, or KCNQ1-Gly589Asp), and time (−2 h, 0 h) were included as ﬁxed
effects. In both models, the WT KCNQ1 was used as the reference KCNQ1
environment. The residual plots were inspected for deviations from normality and
homoscedasticity, and the P-values were calculated using Satterthwaite’s
approximation for the degrees of freedom. These analyses were carried out using R
(version 3.3.3) with packages lme454 (version 1.1-13) (https://cran.r-project.org/
package=lme4) and lmerTest (version 2.0-33) (https://CRAN.R-project.org/
package=lmerTest).
The CRF-induced increases in ACTH secretion were estimated by
calculating fold inductions for each four environments by dividing the ACTH
concentrations, measured 2 h after CRF administration (+2 h), by the baseline
concentration (average of ACTH concentrations measured at −2 h and 0 h),
and subjecting these values to ANOVA. These analyses were carried out
using Graph Pad Prism (version 7.01). P< 0.05 was accepted to indicate
statistical signiﬁcance.
Immunoﬂuorescence and mRNA in situ hybridization. Wild-type CD1 mouse
embryos and postnatal pituitaries were ﬁxed in 4% neutral buffered formalin for
16 h, dehydrated through an increasing ethanol series and parafﬁn-embedded using
standard protocols. Sections were cut at 4 μm and mounted on Superfrost plus
slides. For immunoﬂuorescence, antigen retrieval was carried out in a pressure
cooker in citrate buffer, pH 6.0. Fluorescence detection was performed using
speciﬁc antibodies against KCNQ1 (1:300 dilution, Santa Cruz sc365186 mouse
monoclonal) and against GH (1:1000 dilution, National Hormone and Peptide
Program AFP-564180 rabbit polyclonal, detected with goat anti-rabbit 488 1:300
dilution, Thermo Fisher A11008), with biotin ampliﬁcation for KCNQ1 (biotiny-
lated goat anti-mouse 1:350 dilution, Abcam ab6788; Streptavidin-555 1:500,
Thermo Fisher S32355). Slides were incubated with Hoechst for 10 min (1:10,000,
Thermo Fisher H3570) before mounting. For duplex mRNA in situ hybridization,
slides were pretreated by boiling for 10 min55 and hybridized with speciﬁc probes
against Kcnq1 (channel 1, Cat. No. 507611 target region 827-2024—exons 5–16
(NM_008434.2)), Gh (channel 2, Cat. No. 445361-C2 target region 9-630—exons
1–5 (NM_008117.3)), Ghrh (channel 2, Cat. No. 470991-C2 target region 2-483—
exons 1–5 (NM_010285.3)) and Lhb (channel 2, Cat. No. 478401-C2 target region
26-503—exons 2–3 (NM_008497.2)) (all ACDBio). The RNAscope 2.5 HD Duplex
Assay kit (ACDBio) was used according to the manufacturer’s recommendations,
with the following adaptations to increase signal detection: incubation in ampli-
ﬁcation 9 was extended to 1 h, and the Green B to Green A reagent ratio was
increased to 1:30.
RT-PCR ampliﬁcation of KCNQ1. A 213-bp fragment of KCNQ1 complementary
DNA (cDNA) was ampliﬁed from human hypothalamic cDNA (Clontech, pre-
pared from the hypothalami of 30 male/female Caucasians, aged 15–68 years, after
sudden death), or, as a positive control, from the cardiac cDNA library of a 59-
year-old male donor (Amsbio) with cDNA-speciﬁc primers (Supplementary
Table 1, HuKCNQ1_F+R). β-actin served as a reference gene. Similarly, a 186-bp
fragment of KCNQ1 cDNA was PCR-ampliﬁed from human pituitary gland cDNA
(Clontech, normal pituitary gland pooled from 12 male/female Caucasians, ages
18–52; cause of death: trauma) with cDNA speciﬁc primers (Supplementary
Table 1, HuKCNQ1_F2+R2). GAPDH served as a reference gene. Additionally, a
172-bp fragment of KCNE2 cDNA was ampliﬁed from the human pituitary gland
cDNA and the human hypothalamic cDNA with cDNA-speciﬁc primers. The PCR
products were visualized on 1.5% agarose gel (Supplementary Fig. 4).
Cloning of the KCNQ1 expression vectors for AP-MS. To generate Gateway
entry clones from Human KCNQ1 and the Arg116Leu, Pro369Leu, Gly589Asp
mutants, ﬂanking attB sites were generated using PCR, followed by Gateway BP
reaction. The corresponding entry clones were then used to generate C-terminally
tagged expression vectors (pcDNA5/FRT/TO/BioID/StrepII/HA/GW) via Gateway
LR recombination.
Afﬁnity puriﬁcation. For afﬁnity puriﬁcation, tetracycline-inducible Flp-In T-REx
293 cell lines expressing KCNQ1 wild type and other mutations were generated as
described56. In brief, the cells were co-transfected with the tagged-KCNQ1
expression constructs and pOG44 vector (for Flp-recombinase expression, Invi-
trogen) using FuGENE 6 transfection reagent (Promega). After 2 days, transfected
cells were selected in Hygromycin B (100 mg/ml; Invitrogen) containing medium
for 3 weeks. The positive clones containing stable isogenic tagged-KCNQ1 (wt and
mutants) were expanded and for each construct ∼5 × 107 cells (5 × 15 cm dishes) in
three biological replicates were induced with 1 μg/ml doxycycline (MP Biomedi-
cals) for 24 h. After induction, cells were washed with 0.1 mM MgCl2, 0.1 mM
CaCl2 in PBS and harvested in 1 mM EDTA-PBS. Cells were pelleted by cen-
trifugation 400 × g, 5 min, 4 °C. Cell pellets (~5 × 107 cells) were lysed in 3 ml of
HENN-lysis buffer (50 mM HEPES pH 8.0, 5 mM EDTA, 150 mM NaCl, 50 mM
NaF, 0.5% NP40, 1 mM DTT, 1.5 mM Na3VO4, 1 mM PMSF, and 1× protease
inhibitors cocktail; Sigma) on ice. Cleared cell lysates were loaded on spin columns
(Bio-Rad, USA) containing 200 ml of Strep-Tactin beads (IBA GmbH), washed
thrice with 1 ml HENN-lysis buffer and 4× with 1 ml HENN buffer. Bound pro-
teins were eluted with 900 μl of elution buffer (0.5 mM Biotin; Pierce).
Mass spectrometry. For liquid chromatography–mass spectrometry (LC–MS/MS)
samples were prepared as follows: cysteine bonds were reduced with 5 mM Tris (2-
carboxyethyl)phosphine (TCEP) (Sigma-Aldrich) for 20 min at 37 °C and alkylated
with 10 mM iodoacetamide (Fluka, Sigma-Aldrich) for 20 min at room tempera-
ture in the dark. A total of 1 μg trypsin (Promega) was added and samples digested
overnight at 37 °C. Samples were quenched with 10% triﬂuoroacetic acid (TFA)
and puriﬁed with C-18 Micro SpinColumns (The Nest Group) eluting the samples
to 0.1% TFA in 50% acetonitrile (ACN). Samples were dried by vacuum con-
centration and peptides were reconstituted in 30 μl buffer A (0.1% TFA and 1%
ACN in LC–MS grade water) and vortexed thoroughly.
LC–MS/MS analysis was performed on an Orbitrap Elite ETD hybrid mass
spectrometer using the Xcalibur version 2.2 SP 1.48 coupled to EASY-nLCII-
system (all from Thermo Fisher Scientiﬁc) via a nanoelectrospray ion source. In
total, 6 μl and 5 μl of peptides were loaded from Strep-Tag and BioID-samples,
respectively. Samples were separated using a two-column setup consisting of a C18
trap column (EASY-Column 2 cm × 100 μm, 5 μm, 120 Å, Thermo Fisher
Scientiﬁc), followed by C18 analytical column (EASY-Column 10 cm × 75 μm, 3
μm, 120 Å, Thermo Fisher Scientiﬁc). Peptides were eluted from the analytical
column with a 60 min linear gradient from 5 to 35% buffer B (buffer A: 0.1% FA,
0.01% TFA in 1% acetonitrile; buffer B: 0.1% FA, 0.01% TFA in 98% acetonitrile).
This was followed by 5 min 80% buffer B, 1 min 100% buffer B followed by 9 min
column wash with 100% buffer B at a constant ﬂow rate of 300 nl/min. Analysis
was performed in data-dependent acquisition mode where a high resolution
(60,000) FTMS full scan (m/z 300–1700) was followed by top20 CID-MS2 scans
(energy 35) in ion trap. Maximum ﬁll time allowed for the FTMS was 200 ms (Full
AGC target 1,000,000) and 200 ms for the ion trap (MSn AGC target 50,000).
Precursor ions with more than 500 ion counts were allowed for MSn. To enable the
high resolution in FTMS scan preview mode was used.
Data processing. SEQUEST search algorithm in Proteome Discoverer software
(Thermo Fisher Scientiﬁc) was used for peak extraction and protein identiﬁcation
with the human reference proteome of UniProtKB/SwissProt database (www.
uniprot.org). Allowed error tolerances were 15 ppm and 0.8 Da for the precursor
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and fragment ions, respectively. Database searches were limited to fully tryptic
peptides allowing one missed cleavage (in peptide mapping semi-tryptic with one
missed cleavage allowed), and carbamidomethyl +57,021 Da (C) of cysteine residue
was set as ﬁxed, and oxidation of methionine +15,995 Da (M) as dynamic mod-
iﬁcations. For peptide identiﬁcation FDR was set to <0.05.
The high-conﬁdence protein–protein interactions were identiﬁed using
stringent ﬁltering against control contaminant database. The bait normalized
relative protein abundances (% to the bait) were calculated from the spectral
counts. Each average and SD was calculated from three biological replicates. The
high conﬁdence protein–protein interactions data were imported into Cytoscape
3.4.0 for the visualization combined with the known protein-protein interactions
from PINA2 (Protein Interaction Network Analysis http://cbg.garvan.unsw.edu.au/
pina/)57. Protein complexes were annotated against CORUM database58 and Gene
Ontology term of biological pathway enrichment analysis was using DAVID
(https://david.ncifcrf.gov/)59 (Supplementary Fig. 7).
Molecular modeling of the KCNQ1 Pro369Leu mutant. Coordinates for the
KCNQ1 proximal CT domain in complex with CaM (PDB code 4V0C), derived
from the crystal structure14, were used to prepare the model. Pro369 was mutated
to Leu, selecting the most populated rotamer using Coot60. The molecular graphics
were prepared in PyMol (Supplementary Fig. 2a).
Pull-down assay. The three KCNQ1 Pro369Leu mutant CT constructs (pET Duet
(Merck) with sequential HisTag and TEV protease sequences fused to (i) KCNQ1
352-622 H620A Δ406–504; (ii) 352–539; (iii) 352–539 Δ406–504 in multi-cloning
site I with CaM inserted into multi-cloning site II) were co-expressed with CaM as
described14. Cell paste was suspended in lysis buffer (50 mM sodium phosphate
pH= 8, 300 mM NaCl, 0.1% Triton X-100), sonicated, and clariﬁed by cen-
trifugation. Supernatant (2 ml) was incubated with Ni2+-NTA beads (50 μl) for 1 h
at 4 °C. Beads were then washed three times with wash buffer (50 mM sodium
phosphate pH= 8, 300 mM NaCl, 0.5% Triton X-100, 15 mM imidazole). A sample
of the ﬁnal wash was kept for analysis. Elution from beads was performed by
incubation for 15 min with elution buffer (50 mM sodium phosphate pH= 8,
300 mM NaCl, 250 mM imidazole). Samples were analyzed by SDS-PAGE and
immunoblot was probed with anti-6×His-peroxidase mouse monoclonal (Roche,
cat. no. 11965085001, 1:500 dilution of manufacturer’s suspended lyophilizate) and
anti-CaM mouse monoclonal (Millipore, cat. no. 05-173, 1:1000 dilution of sup-
plied manufacturer’s solution) antibodies (Supplementary Fig. 2b).
Immunohistochemistry in human samples. Human fetuses (11 weeks post
amenorrhea, n= 3) were immersion-ﬁxed in 4% paraformaldehyde in 0.1 M
phosphate-buffer saline (PBS) (pH 7.4) for 3 weeks at 4 °C, cryoprotected in
30% sucrose in PBS for 48 h, embedded in Tissue Tek (Miles), and frozen in
liquid nitrogen. Tissues were cryosectioned at 16 μm. Localization of KCNQ1
was accomplished by using immunoﬂuorescence procedures as previously
described61 (Supplementary Fig. 1). Brieﬂy, sections were blocked in an incubation
solution containing PBS pH 7.4, 0.3% Triton X-100 (TBS-T; Sigma, T8787) with
10% normal donkey serum (NDS; D9663; Sigma) for 2-h at room temperature
(RT). After blocking, sections were incubated for 48-h at 4 °C with a rabbit
polyclonal anti-KV7.1 (KCNQ1) antibody (#APC-022, Alomone labs) diluted
1:200 in a solution containing PBS pH 7.4, 0.3% Triton X-100 and 10% normal
donkey serum. For controls in each immunolocalization procedure, PBS was
substituted for the primary antibody. After PBS rinses, immunoreactivity was
revealed using an Alexa-Fluor 488-conjugated secondary antibody (1:400; Life
Technologies, reference Molecular Probes, Invitrogen, A21206) for 90-min at RT.
After PBS washes, sections were incubated with 0.02% Hoechst (H3569;
Invitrogen) in PBS for 15-min at RT and coverslipped with mowiol medium
(Sigma, Cat. #81381).
Sections were examined using an Axio Imager.Z1 ApoTome microscope (Carl
Zeiss, Germany) equipped with a motorized stage and an AxioCam MRm camera
(Zeiss). For confocal observation and analyses, an inverted laser scanning Axio
observer microscope (LSM 710, Zeiss) with an EC Plan NeoFluor×100/1.4
numerical aperture oil-immersion objective (Zeiss) was used with an argon laser
exciting at 488 nm (Imaging Core Facility of IFR114, of the University of Lille 2,
France).
Subject details and ethics. Human embryos (<GW9) and fetuses (>GW9) were
obtained from voluntarily terminated pregnancies with the parent’s written
informed consent (Gynaecology Hospital Jeanne de Flandres, Lille, France). Tissues
were made available in accordance with the French bylaw (Good practice
concerning the conservation, transformation and transportation of human tissue to
be used therapeutically, published on December 29, 1998).
Permission to use non-pathological human fetal tissues was obtained from the
French Agency for Biomedical Research (Agence de la Biomédecine, Saint-Denis la
Plaine, France, protocol no. PFS16-002).
Data availability. All relevant data are available from the authors.
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